IDVYNSO Drug Patent Profile

« Back to Dashboard

When do Idvynso patents expire, and what generic alternatives are available?

Idvynso is a drug marketed by MSD and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in IDVYNSO is doravirine; islatravir. One supplier is listed for this compound. Additional details are available on the doravirine; islatravir profile page.

DrugPatentWatch^® Generic Entry Outlook for Idvynso

Idvynso will be eligible for patent challenges on April 20, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 20, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IDVYNSO

US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IDVYNSO

IDVYNSO is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes			Y	Y
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes				Y
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes

International Patents for IDVYNSO

See the table below for patents covering IDVYNSO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E388958
Canada	2502109	DERIVE DE 2-HALOADENOSINE AVEC SUBSTITUTION SUR LE CARBONE EN POSITION 4' (4'-C-SUBSTITUTED-2-HALOADENOSINE DERIVATIVE)
Germany	602005005240
European Patent Office	1589026	Dérivés de l'adénosine 2-halogénée et substituée en 4'-C (4'-C-Substituted-2-Haloadenosine derivative)
Spain	2300892

Supplementary Protection Certificates for IDVYNSO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2924034	C02924034/01	Switzerland		PRODUCT NAME: DORAVIRIN, LAMIVUDIN UND TENOFOVIRDISOPROXIL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67066 17.12.2019
2924034	SPC/GB19/024	United Kingdom		PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL; REGISTERED: UK EU/1/18/1333/001-002 20181122; UK PLGB 5305/0015 20181122
2552902	C20190024 00304	Estonia		PRODUCT NAME: DORAVIRIIN;REG NO/DATE: EU/1/18/1332 27.11.2018
2924034	C201930027	Spain		PRODUCT NAME: DORAVIRINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN COMBINACION CON LAMIVUDINA Y TENOFOVIR DISOPROXILO FUMARATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1333; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1333; DATE OF FIRST AUTHORISATION IN EEA: 20181122
2924034	2019C/005	Belgium		PRODUCT NAME: DORAVIRINE,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT IN COMBINATIE MET LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAARZOUT, IN COMBINATIE MET TENOFOVIR OF EEN ESTER DAARVAN, IN HET BIJZONDER EEN DISOPROXIL ESTER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER EEN FUMARAAT ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1333/001-002 20181126